Impact of Sex on the Pharmacokinetics and Pharmacodynamics of 1% Tenofovir Gel.
BACKGROUND
Tenofovir (TFV) gel partially protected against human immunodeficiency virus (HIV) in one but not subsequent trials. The disappointing results were attributed largely to poor adherence. However, timing of gel application relative to sex may impact pharmacokinetics and contribute to outcomes. Thus, we conducted a single-dose pharmacokinetic study of TFV gel applied 1 or 24 hours before or 1 hour before and 1 hour after (BAT) sex and compared results with dosing without sex.


METHODS
Twenty-four couples were enrolled; cervicovaginal lavage (CVL) and tissue were collected 2 hours after sex with matching timed collections at no sex visits and assayed for drug concentrations and CVL anti-HIV activity.


RESULTS
Compared with dosing without sex, median TFV concentrations after sex decreased 72% and 78% (P < .001) in CVL, 75% and 71% (P < .001) in vaginal tissue, and 75% (P = .06) and 55% (P < .001) in cervical tissue with -1 hour and -24 hour dosing, respectively. Median concentration of TFV-diphosphate also decreased significantly in cervical tissue with -1 hour, dosing. BAT dosing resulted in drug levels at least as great as those in the absence of sex. Percent inhibition of HIV infection by post-coital CVL increased significantly from median (interquartile range) of 55% (54%) in the absence of gel to 99% (7%), 77% (57%), and 100% (0.4%) with -1 hour, -24 hour, or BAT dosing, respectively, and correlated significantly with drug concentration.


CONCLUSIONS
Timing of TFV gel application relative to sex significantly impacts drug levels. BAT dosing or sustained delivery may be optimal for preexposure prophylaxis.
Departments of Pediatrics and Microbiology-Immunology, Albert Einstein College of Medicine, Bronx, New York.
Betsy C
BC
Herold
Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh, School of Medicine, Pennsylvania.
Beatrice A
BA
Chen
Department of Medicine, Case Western Reserve, Cleveland, Ohio.
Robert A
RA
Salata
Department of Medicine (Clinical Pharmacology), Johns Hopkins University School of Medicine, Baltimore, Maryland.
Mark A
MA
Marzinke
Statistical Center for HIV/AIDS Research & Prevention, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Clifton W
CW
Kelly
Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh, School of Medicine, Pennsylvania.
Charlene S
CS
Dezzutti
Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh, School of Medicine, Pennsylvania.
Ian
I
McGowan
Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh, School of Medicine, Pennsylvania.
Beth
B
Galaska
Family Health International 360, Durham, North Carolina.
Lisa
L
Levy
Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
Jeanna M
JM
Piper
Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh, School of Medicine, Pennsylvania.
Sharon
S
Hillier
Department of Medicine (Clinical Pharmacology), Johns Hopkins University School of Medicine, Baltimore, Maryland.
Craig W
CW
Hendrix
D000293:Adolescent; D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage* / Q000032:analysis / Q000493:pharmacokinetics* / Q000494:pharmacology; D002853:Chromatography, Liquid; D005260:Female; D005782:Gels / Q000008:administration & dosage*; D006678:HIV / Q000187:drug effects; D015658:HIV Infections / Q000517:prevention & control*; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D065129:Pre-Exposure Prophylaxis / Q000379:methods*; D012737:Sex Factors; D053719:Tandem Mass Spectrometry; D000068698:Tenofovir / Q000008:administration & dosage* / Q000032:analysis / Q000493:pharmacokinetics* / Q000494:pharmacology; D013997:Time Factors; D044364:Vaginal Douching; D055815:Young Adult
D019380:Anti-HIV Agents; D005782:Gels; D000068698:Tenofovir
HIV; MTN-011; pharmacokinetics; post-coital; tenofovir gel